[Therapy of rheumatic diseases with inosiplex].
27 patients (13 rheumatoid arthritis, RA; 4 systemic lupus erythematosus, SLE; 5 systemic sclerosis, PSS; 5 undifferentiated connective tissue disease, UCTD) were treated with inosiplex for more than 23 months (7.7 +/- 1.3). Clinical improvement was impressive by the end of the first month of therapy in 7 patients with moderate active RA (p less than 0.01), and 5 of these patients treated for more than 8 months continued to do well (p less than 0.05). In contrast, patients with very active RA did not show any clear-cut improvement. In the other diseases studied, 5 patients responded rapidly (reduction in arthritis, improvement of pulmonary involvement). A concomitant rise in the T4/T8- (helper-/suppressor-) cell ratio with increased numbers of T4+-cells was observed in patients with RA and PSS. Our data suggest that some patients with rheumatic diseases may benefit from long-term treatment with inosiplex.
Becker
H
H
Loers
E
E
Helmke
K
K
Federlin
K
K
D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D003095:Collagen Diseases / Q000188:drug therapy; D003165:Complement System Proteins / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007136:Immunoglobulins / Q000378:metabolism; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000276:immunology; D012595:Scleroderma, Systemic / Q000188:drug therapy
D000974:Antibodies, Antinuclear; D007136:Immunoglobulins; D007288:Inosine; D003165:Complement System Proteins; D011239:Prednisolone; D007542:Inosine Pranobex
Therapie rheumatischer Erkrankungen mit Inosiplex.